By BullScreen Editorial Team 
Shares of Mahamaya Lifesciences Limited surged 5% to hit the upper circuit at ₹155.40 on Friday, driven by fresh buying interest after ace investor Vijay Kishanlal Kedia increased his stake in the company. The stock gained momentum from its previous close of ₹148, reflecting strong investor sentiment.
The rally follows stake accumulation by Kedia’s investment arm, Kedia Securities Private Limited, which recently acquired 1.69 lakh shares at an average price of ₹146.36 per share, amounting to ₹2.48 crore. This comes after an earlier purchase of 8.92 lakh shares at ₹140 per share, taking the total holding to 4.53%, signaling continued confidence in the company’s growth outlook.
Mahamaya Lifesciences Limited, a micro-cap agrochemical stock, operates in manufacturing and exporting pesticide formulations and bioproducts aimed at improving crop yield and soil health. The company’s diversified product portfolio and export presence have positioned it well within the evolving agrochemicals market.
The company had launched its IPO in November 2025 to raise ₹70.44 crore, with plans to expand manufacturing capacity, invest in a new facility, and strengthen working capital. These strategic initiatives are expected to support long-term growth.
Financially, the company reported steady performance, with revenue rising 11.64% to ₹163 crore in H1 FY26, while net profit increased 14.29% to ₹8 crore. Over the past three years, it has delivered robust growth, with revenue and profit CAGR of 43.15% and 63.03%, respectively.
The latest stake hike by Vijay Kedia is seen as a positive signal for investors tracking micro-cap opportunities in the agrochemical space, often viewed as a proxy for rising agricultural demand and improving rural economy trends.